Microsoft word - 2013_cacs_symposium_program_long061113.docx
2013 Tri-State CACS Annual Symposium 
New Challenges and Opportunities 
Facing the Global Chemical Enterprise 
The Department of Medicinal Chemistry 
Ernest Mario School of Pharmacy, Rutgers University 
8:30 am – 4:00 pm 
Saturday, June 22, 2013 
Busch Campus Center 
Rutgers University 
604 Bartholomew Rd 
Piscataway, NJ 08854 
www.tristatecacs.org 

Job Fair and Career Consultation 
Abstracts & Speaker Biosketches 
 Morning session 
 Afternoon session 
Tri-State CACS Officers 
 Website: http://www.tristatecacs.org/ 
 Email: [email protected] 


Foreword 
 
Welcome to the 2013 Tri-State CACS Annual Symposium! 
On behalf of the Tri-State CACS Board, we would like to express our sincerest appreciation to our sponsors and 
volunteers for their support and contributions to this symposium and to our organization. 
We are living in a world that is also changing constantly. The American chemical and pharmaceutical 
industries as a whole and the Chinese-American chemical professionals in particular are presented with 
unprecedented challenges and opportunities in this rapidly shifting global environment. For a business to 
survive and to thrive, it must constantly innovate and reinvent itself, locally and globally. Chemical and 
pharmaceutical businesses are no exceptions. For each participant in the chemistry enterprise, one must realize 
that he/she needs to constantly sharpen his/her existing skills and promptly master new skills in order to 
succeed. 
Again, we are very pleased to have a group of prominent leaders from chemical, pharmaceutical, educational, 
legal organizations as well as small businesses to join us at this year's symposium. We are extremely pleased to 
have the first Chinese American President of the American Chemical Society, Dr. Marinda Li Wu, join us this 
year. These leaders will share their wisdom and perspectives on "New Challenges and Opportunities Facing 
the Global Chemical Enterprise", that will inspire, educate and entertain our curious minds, no matter which 
branch of the chemical enterprise we are interested in. We thank all of the speakers for taking the time to share 
their visions about the future growth drivers and their leadership experience as well as to provide career advices. 
The presentations will be accompanied by a vendor exhibition, job search consultation, advertisement of new 
job openings from both local and overseas companies. In addition, this symposium serves as an excellent 
networking opportunity for chemical professionals to meet and interact with people from diverse chemical 
background. 
We thank you for making this symposium part of your weekend and for making CACS a more valuable 
professional organization to all of us. 
Wendy Zhong, Ph.D. 
Mark Zhen, Ph.D. 
Fanwen Zeng, Ph.D. 
Immediate Past-President 
 Website: http://www.tristatecacs.org/ 
 Email: [email protected] 

Program Schedule 
Registration / Breakfast & Coffee 
Morning Session 
(Session Chairs: Drs. Shel Zhang and Min Liu) 
Globalized Chemistry Enterprise and Global Challenges 
Opening Remarks, Wendy Zhong, Ph.D., 2013 President, Tri-State CACS 
Marinda Li Wu, Ph.D., 2013 President, American Chemical Society 
Partners for Progress and Prosperity 
Brian Maurer, Global R&D Director, the Dow Chemical Company and Chairman of the Chemistry 
Council of New Jersey 
A New Renaissance for the Chemical Industry 
 
10:10 
Zhihong Ge, Ph.D., Executive Director of Global Analytical Chemistry, Merck Research Laboratory 
Analytical Technology to Enable Drug Discovery and Development 
Vendor Show, Coffee Break & Networking  
Vivian Yao, Worldwide Vice President of Human Resources, Global Surgery Innovation, Johnson & 
Johnson 
Career Development and Talent Management in Medical Devices 
Tian Yang, Ph.D., Director of Preclinical Drug Evaluation, Global Alliance for Tuberculosis Drug 
Discovery and Development 
Drug Safety Challenges in Drug Discovery –Examples in Tuberculosis Drug Discovery and Treatment  
Lunch Break (on site) 
Afternoon Session 
(Session Chairs: Drs. Mark Zhen and Peng Zhang) 
Sharpen Your Saw for Global Opportunities 
Hai-Lung Dai, Ph.D., Laura H. Carnell Professor of Chemistry, Provost and Sr. Vice President for 
International Affairs, Temple University 
New Paradigms for Educating Chemistry Professionals in a Globalized World 
Fang Liu, Ph.D., Shareholder and Attorney at Law, Buchanan Ingersoll & Rooney, PC 
Patent Attorney – Alternative Career Opportunity 
Vendor Show, Coffee / Ice Cream Break / Networking 
Changxi Miao, Ph.D., Vice Chief Engineer, Shanghai Research Institute of Petrochemical 
Technology, SINOPEC 
Recent Advance in Technologies of Coal to Chemicals Developed by SINOPEC 
Gautam Saxena, President & CEO, Integrated Analysis Inc. 
 Private Cloud Informatics Technology for Mass Spectrometry: 100x Faster, 30% More Identifications, Zero Hardware and 
Global Collaborations 
Closing Remarks, Mark Zhen, Ph.D., 2013 President-Elect, Tri-State CACS 
 Website: http://www.tristatecacs.org/ 
 Email: [email protected] 

 Website: http://www.tristatecacs.org/ 
 Email: [email protected] 

Vendor Show 
9:00AM – 4:00PM 
(Session Chairs: Drs. Jian Wang and Min Liu) 
The Dow Chemical Company 
http://www.dow.com 
Therm Fisher Scientific 
http://www.agilent.com 
http://www.waters.com 
Primera Analytical Solutions 
Johnson and Johnson 
http://www.jnj.com 
Analytical Sales 
SINOPEC (Shanghai) 
Shimadzu 
Job Fair and Career Consultation 
9:00AM – 4:00PM 
(Coordinators: Drs. Lijuan Wang and Fanwen Zeng) 
Job fair will connect job seekers with hiring managers or job postings from companies in the US and China, 
such as SINOPEC Shanghai Research Institute of Petrochemical Technology, Shimadzu Scientific Instruments, 
Johnson and Johnson and The Dow Chemical Company. Please come to the booth area for more details. 
Mr. Bill Suits, ACS career consultant, will provide free consultation about how to get a job, keep a job and build a successful career. 
Ms. Kathryn Moore and Dr. Jianxin Zhang from USDA will have a general career consultation on how to search and apply for job opportunities at government agencies such as USDA. 
 Website: http://www.tristatecacs.org/ 
 Email: [email protected] 

Symposium Chair 
Programs 
Fanwen Zeng, Wendy Zhong, Lijuan Wang, Shel Zhang, Min Liu, 
Yingchun Lu, Mark Zhen, Yijun Lu, Rachel Xiaoqiu Wu, Peng 
Vendor Show 
 Jian Wang, Min Liu, Fanwen Zeng, Yijun Lu, Yingchun Lu 
Job Fair/ 
Career Consultation 
Lijuan Wang, Fanwen Zeng 
 Baoqing Ma, Fangbiao Li, Sam Xiang Zhu, Noah & Maria Li, 
Amber Zhen, Cindy & Patrick Ma, George Zeng, Lorraine Zhang 
Food/Beverage Services 
Longqin Hu, Baoqing Ma, Yabin Lei, Sam Xiang Zhu 
Photography 
Hongwei Shen, Fanwen Zeng 
Jack Zhigang Li, Hongwei Shen, Yabin Lei, Honghong Li 
 Website: http://www.tristatecacs.org/ 
 Email: [email protected] 

Abstracts & Speaker Biosketches 
Morning Session 
Marinda Li Wu, Ph.D., 2013 President, American Chemical Society 
"Partners for Progress and Prosperity" 
 
Abstract: A major challenge facing the global chemistry enterprise is the need to promote a deeper appreciation 
and understanding from our policy makers and the general public for the wonderful benefits that chemistry 
contributes to everyday life. A brief overview of the American Chemical Society (ACS) and highlights of 
various public outreach programs will be presented. My personal professional journey and experiences with 
successful ways to show the general public the valuable contributions to society resulting from chemistry and 
science will be shared. The audience should gain some ideas of how to effectively share enthusiasm for 
chemistry and its benefits with young students and the general public through the ACS vision: "Improving 
people's lives through the transforming power of chemistry." I will conclude by discussing highlights of my 
ACS Presidential initiatives for 2013 and welcome your feedback and ideas. 
Bio: Dr. Marinda Li Wu received a B.S. cum laude with Distinction in Chemistry from 
The Ohio State University in 1971 and a Ph.D. in Inorganic Chemistry from the 
University of Illinois in 1976. With over thirty years of experience working in the 
chemical industry, she enjoyed many years working for Dow Chemical R&D as well as 
Dow Plastics Marketing forging partnerships between industry, education, government 
and communities. Dr. Wu also has entrepreneurial experience with various small 
chemical companies and startups including "Science is Fun!" which she founded to 
engage young students in the excitement of science and enhance public awareness of the 
importance of supporting and improving science education. 
As an ACS member for over forty years, Dr. Wu has served in many leadership roles at 
both the local and national levels for the American Chemical Society. Dr. Wu was elected 
to the ACS Board of Directors and served as Director-at-Large since 2006. In 2011, she was elected to the 
Presidential succession of the American Chemical Society. As ACS President-Elect for 2012, she was invited to 
give plenary lectures worldwide and made an honorary member of the Romanian Chemical Society and Polish 
Chemical Society. She serves as ACS President in 2013 and Immediate Past President in 2014. 
Dr. Wu serves on the University of Illinois Chemistry Alumni Advisory Board, the International Advisory Board 
for the 45th IUPAC World Chemistry Congress 2015, the ACRICE-1 (1st African Conference on Research in 
Chemistry Education) International Advisory Board, and the Board of Directors for the Chinese-American 
Chemical Society. She holds 7 U.S. Patents and has published a polymer textbook chapter and numerous articles in 
a variety of journals and magazines over the years. 
 
Brian Maurer, Global R&D Director – Dow Chemical and Chairman of the Chemistry Council of New Jersey 
"A New Renaissance for the Chemical Industry" 
Abstract: Not so long ago, many economists, policymakers, and business leaders had written off chemical 
manufacturing in this nation and believed the sector's decline was irreversible. However, recent shale gas 
developments have created a renewed optimism for the business of chemistry. This presentation will review the 
 Website: http://www.tristatecacs.org/ 
 Email: [email protected] 
opportunities and challenges for a chemical manufacturing renaissance in the United States as well as the state of New Jersey. 
 
Bio: Brian R. Maurer is a global Sr. R&D Director for the Performance Plastics 
division of the Dow Chemical Company. During his 30+ years with Dow Chemical, 
more than half of his career was spent in three different global R&D Director roles. 
Most recently he served as Sr. R&D Director of Dow's Electrical & 
Telecommunications business. His global DE&T R&D organization developed novel 
solutions for the effective transmission and distribution of power, video, voice and data. 
Brian also served as Sr. R&D Director for Dow's Water Soluble Polymer business which 
developed new technologies for pharmaceutical, personal care, food, construction 
chemical, and paint applications. Finally, he served as Sr. R&D Director of Dow 
Automotive which successfully developed plastic, fluid, film and foam technologies 
used in auto interior and exterior applications. 
 
From an external perspective, Brian serves as chairman of the Chemistry Council of New Jersey. The 
CCNJ supports 55,000 employees, generates $25-30B in annual revenue, and is comprised of 125 
member companies from across the state of NJ. From an academic perspective, he serves on technical 
advisory boards at Georgia Tech (National Electric Energy Testing Research Applications Center), 
Rutgers University (Department of Chemistry & Chemical Biology) and Central Michigan University 
(College of Science & Technology). He is currently a member of the Society of Plastics Engineers, the 
Society of Automotive Engineers, and the American Chemical Society. 
Brian is a chemistry graduate of Central Michigan University and has completed executive MBA training at Thunderbird University in Glendale, Arizona as well as IMD in Lausanne, Switzerland. He is the author of ten patents/applications, was a recipient of Dow's "Inventor of the Year Award," received nine external innovation awards, and received Dow's "Genesis Award" for excellence in people leadership. 
Vivian Yao, Worldwide Vice President of Human Resources, Global Surgery Innovation, Johnson & Johnson 
"Career Development and Talent Management in Medical Devices" 
Vivian (Ying) Yao is the Worldwide Vice President of Human Resources for 
Ethicon's Global Surgery Innovation Team. She drives the innovation strategic 
capability development and talent agenda for the $12 billon global businesses. Vivian 
also serves on the Johnson & Johnson Human Resources Council, as well as, the 
MD&D Global Human Resources Leadership team. 
Vivian joined Johnson & Johnson from General Electric (GE) where she served as the 
Organization and Staffing Leader responsible for global talent development across the 
company's commercial and communications functions, representing roughly 40,000 
employees. Working in support of GE's executive commercial leadership team, 
Vivian was responsible for building the commercial capabilities and global talent 
pipeline in support of the GE platforms of ecomagination, devoted to reducing environmental impact with new technologies, and healthymagination, focused on achieving sustainable health through innovation. During her ten- year career at GE, Vivian served in many progressive HR generalist and business partner roles, including partner to GE Healthcare's Life Science Americas business. She has served as the architect of new commercial 
 Website: http://www.tristatecacs.org/ 
 Email: [email protected] 
operating models, business integrations and new capability builds globally and is well recognized as a leader 
who drives employee engagement, performance and results. 
Prior to joining GE, Vivian served as a consultant at Chicago-based Towers Perrin and as an HR consultant at 
IBM's Storage System Division in San Jose, CA. 
Vivian spent the early years of her career as an HR Partner for General Motors Asia working in China to 
attract, develop and retain high-performing and high-potential employees. 
Zhihong Ge, Ph.D., Executive Director of Global Analytical Chemistry, Merck Research Laboratory 
"Analytical Technology to Enable Drug Discovery and Development" 
Abstract: The increasing pace of drug discovery and development in recent years demands more efficient and 
innovative approaches for pharmaceutical research. Many emerging trends at Merck and across the industry 
such as platform technologies and novel drug delivery techniques as well as new regulatory requirements have 
posed new challenges for analytical science. In this presentation, examples of recent advances in analytical 
technologies to enable drug discovery and development will be highlighted. 
Bio: Dr. Zhihong Ge is an Executive Director and a leader of the global Analytical 
Chemistry organization which spans Analytical and Physical Chemistry disciplines at 
Merck Research Laboratories. The group is responsible for providing critical 
measurement and analysis capabilities to support small molecule, peptide, siRNA, 
experimental medicine, and Product Value Extension (PVE) pipeline from Discovery to 
Phase IIB. This includes the development of analytical methods and specifications for 
release of drug substance for safety and clinical studies, as well as for control of the 
synthetic process through raw material analysis and in-process testing. She also 
provides analytical data and information for Investigational New Drug (IND) filings. 
Zhihong received her B.S. from Beijing University in 1987 and joined Merck in 
1992 after completing her PhD at University of Washington. During her tenure at Merck, Zhihong has 
participated in many development programs including marketed products Crixivan, Arcoxia and Isentress. In 
1999, she created a Process Analytical Technology (PAT) group within the Process R&D and since then 
introduced numerous "first kind to Merck" PAT technologies to monitor, optimize and control drug substance 
synthetic processes. 
Zhihong has been an author or co-author on more than 30 publications. She was a member of PhRMA PAT 
Expert Working Group and PhRMA LD KIT (Limited Duration Key Issue Team) on Genotoxic Impurities. 
Currently she participates in PhRMA ICH M7 Expert Working Group and International Consortium for 
Innovation and Quality (IQ) Specification team. 
Tian Yang, Ph.D., Director of Preclinical Drug Evaluation, Global Alliance for Tuberculosis Drug Discovery 
and Development. 
 
"Drug Safety Challenges in Drug Discovery – Examples in TB Drug Discovery and Treatment" 
 
Abstract: Decreasing the high attrition rate in drug discovery and development process is a primary goal of the 
pharmaceutical industry. Drug candidates failed to be further development in clinical is mainly due to lack of 
efficacy, adverse drug effect, poor bioavailability, and business/market. Thus one of the main challenges in drug 
discovery and development is to define an appropriate balance between drug efficacy and potential adverse 
effects as early as possible in order to reduce safety-related attrition, particularly in the more expensive late 
 Website: http://www.tristatecacs.org/ 
 Email: [email protected] 
stages of clinical development. A number of in vitro assays have been developed to guide discovery lead optimization to reduce drug safety liabilities including in vitro pharmacological profiling, cell based toxicity, and screening of ion channels. The presentation will discuss in vitro toxicological ‘hit' and optimization strategies. Examples will be given from tuberculosis drug discovery and development. 
 
Bio: Dr. Tian J Yang is Director of Preclinical Drug Evaluation at Global Alliance for 
Tuberculosis Drug Discovery and Development. He is responsible for DMPK/Tox in 
drug candidate optimization and preclinical development. Prior to joining TB Alliance, 
Dr. Yang spent 5 years at Roche Nutley, served as head of enzymology group and then 
head of drug metabolism group. Before working at Roche, Dr. Yang worked as a 
research scientist at DuPont Pharma and BMS for 8 years in optimization of drug 
candidate ADME properties and preclinical development. Dr. Yang received his Ph.D. 
in pharmacology focused on liver injury and protection from Peking Union Medical 
College in 1991. Following two years of postdoctoral research on CNS drug discovery 
at the Uniformed Services University of Health Sciences at Bethesda, MD, he joined the 
NCI/NIH as a staff fellow and senior staff fellow working on CYP monoclonal antibody 
preparation and phenotype of drug and carcinogen metabolism. 
 Website: http://www.tristatecacs.org/ 
 Email: [email protected] 
Afternoon Session 
 
Hai-Lung Dai, Laura H. Carnell Professor of Chemistry, Provost and Sr. Vice President for International 
Affairs, Temple University 
 
"New Paradigms for Educating Chemistry Professionals in a Globalized World" 
 
Abstract: In today's ever more collaborative environment for education and research in a globalized world, 
what lessons can we take from other societies and what new avenues can we explore in educating future 
generations of chemists, or for that matter, scientists? The possibilities range from new paradigms for educating 
secondary science teachers, to collaborative dual degree programs that enhance students' professional 
capabilities, to dual doctoral degrees that both enrich the student's experience as well as the participating 
institutions' ability to conduct research. Teacher education programs, dual bachelor-master degrees program, 
and bilateral doctoral degree programs established at the University of Pennsylvania and Temple University will 
be highlighted as examples. 
Hai-Lung Dai is Provost and Senior Vice President for Academic Affairs, Laura H. 
Carnell Professor of Chemistry, and also continuing to serve as the Senior Vice Provost 
for International Affairs at Temple University. 
A graduate of National Taiwan University, he holds a PhD from the University of California at Berkeley, and was a postdoctoral fellow at the Massachusetts Institute of Technology. In 1984 he joined as faculty at the University of Pennsylvania where he was Chair of the Chemistry Department, funding Director of the Penn Science Teacher Institute, and the Hirschmann-Makineni Professor of Chemistry. During his two-term chairmanship, the Penn Chemistry Department ranked as high as #6 in the nation in terms of sponsored research funding. The chemistry teacher training programs that he created was cited by the National Academies as a model for content preparation for science teachers and he was invited to testify in the US Senate in 2006 on a HR bill 
aimed at science teacher training. In 2007, he moved to Temple University as Dean of the College of Science and Technology. As Senior Vice Provost for International Affairs since 2010, he oversees Education Abroad, which manages study abroad and Temple's overseas campus in Tokyo and Rome; International Programs, which facilitates and manages partnerships with foreign institutions and collaborative educational programs; International Students and Scholars Services; and International Student Recruiting and Admission. Under his leadership, Temple has created new dual bachelor's-master's degree, collaborative bachelor degree programs, and dual PhD degree programs for international students with partner universities in Asia and Europe and a liaison office in Beijing coordinating collaborative programs and student recruiting; vastly expanded Temple's partnerships all over the world; and raised awareness of globalization within Temple's campus. In Feb. of 2013, Dai was appointed to the position of Provost and Senior Vice President for Academic Affairs. In this capacity he oversees a $600 million annual budget that supports the academic functions of 17 colleges and schools. Within the short period after assuming this responsibility, he led the effort to design and implement a new scholarship and financial aid plan that vastly expanded the offerings designed for improving student quality and reducing student debt, started investment in a new faculty recruiting campaign, and launched a series of effort aimed at improving the University's education quality and reputation. 
 Website: http://www.tristatecacs.org/ 
 Email: [email protected] 
 
Fang Liu, Ph.D., Attorney at Law, Shareholder, Buchanan Ingersoll & Rooney PC 
"Patent Attorney – Alternative Career Opportunity" 
 
Abstract 
A daily life of a patent attorney will be discussed as well as how to become a patent attorney and basic patent 
application filing requirements. 
Bio: Fang Liu is a patent attorney with the firm Buchanan Ingersoll & Rooney PC. 
Ms. Liu's practice includes U.S. and foreign patent preparation and prosecution, and 
patentability, validity and non-infringement opinions in matters pertaining to a wide 
array of organic/inorganic chemical arts, such as pharmaceutical chemistry, polymer 
chemistry, petroleum chemistry, nanotechnology, photographic and lithographic 
chemistry, material chemistry, agricultural chemistry, food additives, and coating 
compositions. 
 
Before joining Buchanan, Fang was a patent attorney with one of the largest 
intellectual property boutique firms in Washington, D.C. Prior to her legal career, 
she worked for more than 10 years in research and development as a research 
associate and teaching assistant at several U.S. universities. 
Fang is also a published author who has contributed to a number of articles and books on chemistry-related 
topics. 
While pursuing her Ph.D. in organic chemistry at Purdue University, she studied under Ei-ichi Negishi, the 
Nobel Prize-winning scientist. Fang's postdoctoral adviser, Marye Anne Fox, is a recipient of the National 
Medal of Science, the highest honor bestowed by the United States government on scientists, engineers and 
inventors. 
Changxi Miao, Ph.D., Vice Chief Engineer, SINOPEC Shanghai Research Institute of Petrochemical 
"Recent Advance in Technologies of Coal to Chemicals Developed by SINOPEC" 
Coal to chemicals technologies have made a breakthrough in recent years in China, mainly driven 
by high crude oil price and strong market demand for chemicals. The latest advances in coal to chemicals technologies developed by SINOPEC were reviewed. SINOPEC methanol to olefins (S-MTO) technology has 
been commercialized successfully in 2011. Industrial demo tests of SINOPEC methanol 
to propylene (S-MTP), syngas to ethylene glycol, methanol to xylene (MTX) and SNG 
processes are being carried out. A great progress has been made in the research area of 
methanol to aromatics (MTA), syngas to olefins (GTO) and acetic acid hydrogenation 
technology etc. in lab scale. 
Bio: Changxi Miao received his Ph.D. degree in Physical Chemistry from Fudan 
University in China in 1996. After graduation, he joined SINOPEC as a research staff. In 
2002, he worked at University of California, Berkeley as a visiting scholar. In 2003, he 
 Website: http://www.tristatecacs.org/ 
 Email: [email protected] 
was named Professor. Now he is Vice Chief Engineer of SINOPEC SRIPT and in charge of the R&D of styrene catalyst and technology. Dr. Miao has applied more than 120 patents. He is the author of more than 60 scientific papers in the fields of heterogeneous catalysis and chemical technology. 
Gautam Saxena, President & CEO, Integrated Analysis Inc. 
 
 "Private Cloud Informatics Technology for Mass Spectrometry: 100x Faster, 30% More Identifications, 
Zero Hardware and Global Collaborations" 
 
 Abstract:  
In the world of mass spectrometry, bioinformatics has been argued to be one of the biggest bottlenecks for 
effective use of the mounds of generated MS data. A few of the biggest labs have invested multiple years and 
millions of dollars building custom, proprietary internal informatics solution to address these informatics needs. 
Even back in 2008, we wondered if there was a better way. Many years ago, a startup company that was spun 
off from the University of Maryland approached us. They wanted to know if we could develop an informatics 
solution for their MS needs. Rather than trying to build a custom solution for a single client, we decided to 
approach the problem from the perspective of developing a more general, universally applicable MS informatics 
product using all the knowledge we had gained in developing bid data solutions for clients in other fields. 
We will share the story of the initial customer needs in 2008, how Johns Hopkins University (JHU) became 
ultimately our key client from 2008 to the present day, our missteps along the way (both business and 
technical), and ultimately the five major problems we discovered that almost all MS informatics suffered from: 
1) securely and robustly storing massive amounts of MS data; 2) processing the MS data 100x faster compared 
to traditional approaches by using private cloud technology; 3) enabling true global accessibility and 
collaborations; 4) integrating disjointed MS informatics processes; and 5) eliminating/reducing the hidden costs 
and complexities of these so-called "enterprise informatics" solutions. 
We will conclude with the current state of affairs at JHU, in particular focusing on the exciting companies 
-- with reputable venture capital funding -- that the JHU PIs have started based on the putative biomarkers 
identified using mass spectrometry coupled with the above-referenced informatics solution. 
 
Bio: Gautam Saxena graduated with a degree in Electrical and Computer 
Engineering (1999) from McGill University (Montreal, Canada). During his studies, 
he founded two companies (a software consulting company and a tax company, the 
latter of which was successfully sold.) From 2000 to 2002, he worked as the 
"National Solutions Architect" and then the "Global Solutions Architect" for one of 
the fastest growing and successful Silicon Valley companies, Informatica Inc. In 
those roles, he worked with Informatica's largest clients to outline solutions for their 
big data problems. In 2002, he founded Knights Consulting, which for the first six 
years was a boutique consulting company focusing on big data projects for Global 
100 clients such as National Institute of Health, Oracle, Sun Microsystems, Johns Hopkins University, Phoenix Children's Hospital, Thomson Prometric, and Business Objects. In 2008, he renamed Knights Consulting to Integrated Analysis and began development of a software service which was focused on MS-based informatics. 
 Website: http://www.tristatecacs.org/ 
 Email: [email protected] 
 
Bill Suits ACS Career Consultant 
 
Bio: 
Bill Suits serves as a volunteer ACS Career Consultant who has assisted over 
2000 in transition in the last twenty years. He continues to host monthly Careers 
in Transition meeting in North Jersey. He served as Chair of the North Jersey 
section and Chair of the inaugural MARM Board of directors. He continues as a 
Councilor for North Jersey and has served on LSAC, CEPA and PR and 
Communications committees nationally. After Graduating from the University of 
Wisconsin where he played in the Rosebowl, he worked with Chromatography 
suppliers in sales, marketing and application roles. 
 Website: http://www.tristatecacs.org/ 
 Email: [email protected] 
Tri-State CACS Officers (2013) 
Wendy Wenqing Zhong  
[email protected]  
Mark Yueqian Zhen 
[email protected] 
 Immediate Past-President 
Fanwen Zeng 
 Secretary 
Sunny Xuhong Wang 
[email protected] 
Rachel Xiaoqiu Wu 
[email protected] 
 
Board of Directors 
Lei, Yabin; Li, Jack Zhigang; Liu, Min; Lu, Yingchun; Ma, Baoqing; Shen, 
Hongwei; Wang, Jian; Wang, Lijuan; Wang, Kun; Zeng, Fanwen; Zhen, 
Yueqian (Mark); Zhang, Peng; Zhang, Shel; Zhong, Wendy; Zhou, Boli; 
Zhu, Xiang (Sam). 
 Advisory Board 
Cao, Guang; Cao, Ping; Chang, David Y.; Chen, Chien-Kuang; Chen, Guodong; Chen, K. Y.; Chen, Meng-Hsin; Chen, Shaoqing; Cheung, Hong-Son; Chiang, Joseph; Duh, How-Yunn; Guo, Paul; Ho, Teh C.; Hsieh, Tony Y.; Hu, Kevin; Hu, Longqin; Lan, Shih-Jung; Li, Ge; Ma, Wuping; Qian, Kuangnan; Shi, Shawn; Shih, Neng-Yang; Siew, Ernest; Su, Heng; Sun, Yongkui; Tan, Hock; Wang, Stephen; Wang, Sunny Xuhong; Wang, Yuguang; Wu, Xiaoqiu; Xia, Tianhui; Yeh, Lisa; Zhang, Donglu; Duxi Zhang, Zhang, Hongjian; Zhang, Xumu  
 Website: http://www.tristatecacs.org/ 
 Email: [email protected] 
 Website: http://www.tristatecacs.org/ 
 Email: [email protected] 
Sponsors 
 
Tri-State CACS gratefully acknowledges the following sponsors for their support of Tri-State CACS and this symposium: 
Department of Medicinal Chemistry 
Ernest Mario School of Pharmacy 
Rutgers University 
 Website: http://www.tristatecacs.org/ 
 Email: [email protected] 
Source: http://tristatecacs.org/Conferences/13AS/Program_.pdf
   WEEKLY GLOBAL ENERGY Markets SNAPSHOT  September 1 – September 5, 2014  News you missed during the week…   St Vincent Geothermal Power Plant Could Be Operational By 2018 St. Vincent and the Grenadines Prime Minister, Dr. Ralph Gonsalves,  updating the country on the results of the surface exploration phase of the geothermal project stating that a recent report indicated Mount Soufriere is hosting a high temporary geothermal reservoir of commercial use. Gonsalves further mentioned that if everything "goes well and on scheduled", the geothermal plant is scheduled to begin operations in June 2018. St. Vincent and the Grenadines current peak demand for electricity is 20MW with 5MW generated by hydropower. The government is exploring the development of a 5 to 15 MW geothermal power plant to provide base load power to the country. (Source 
  
   für Hospizhelfer  Hospiz Landesarbeitsgemeinschaft  Niedersachsen e.V.  ©Arbeitsgruppe 17.10.2000  Moderation und Ausarbeitung  Ulrich Sündermann  Hospiz Landesarbeitsgemeinschaft Niedersachsen e.V.  DASEIN Hospiz Nienburg / Weser e.V.  P M L Krankenhaus Nienburg  *Alle Charakterisierungen gelten genauso in der weiblichen Form, und Ausnahmen bestätigen wie immer die Regel. J Stichwort „Palliative Care": Laut Definition (von 1990) der WHO (World Health Organization –Weltgesundheitsorganisation- gegründet 1948) bedeutet „Palliative Care": „Die wirksame, ganzheitliche „care" (Sorge, Obhut, Pflege) von Patienten deren Krankheit nicht mehr kurativ (heilbar) behandelbar ist. Dabei stehen die erfolgreiche Behandlung der Schmerzen und weiterer Symptome (Zeichen von Krankheit) sowie die Hilfe bei psychologischen, sozialen und seelsorgerischen Problemen an erster Stelle. Das Ziel der „Palliative (lateinisch: pallium – der Mantel, übertragen auf Medizin: ummanteln oder umsorgen) Care" ist, die bestmögliche Lebensqualität für Patienten und deren Familie zu erreichen." „Palliative Care" unterstützt Leben und betrachtet Sterben als natürlichen Vorgang. „Palliative Care" will sowohl den Patienten unterstützen um ihm ein möglichst selbstbestimmtes Leben bis zum Tod zu ermöglichen, als auch seinen Angehörigen und Freunden zur Seite zu stehen, damit Sie mit Krankheit und Trauer besser zurechtkommen. Wenn also keine Heilung mehr möglich ist und mit dem baldigen Tod gerechnet wird, gilt es bis zum letzten Atemzug selbst bestimmt zu leben. Dies stellt manchmal in der konkreten Lebenssituation besondere Anforderungen an Hospizhelfer. Anforderungen die selten in Standards geregelt sind und nicht immer auf dem Boden der erlernten klassischen Handlungsweisen erledigt werden können. Besondere Kenntnisse und Maßnahmen sind jetzt erforderlich. Unumstößlich bleibt dabei, dass Hospizhelfer in der Regel keine Krankenpflege leisten. Sicherlich ist es aber von Vorteil, nicht völlig unvorbereitet zu sein. Hier bieten sich Kurse für Pflegende Angehörige an, die von Sozialstationen oder von Krankenkassen durchgeführt werden. In diesen Kursen wird pflegerisches Grundwissen an Laien vermittelt. Die vorliegende Schrift, soll eine Übersicht über Maßnahmen geben, die dem Schwerkranken und Sterbenden Erleichterung, Linderung und Hilfe bieten. Es gilt, den Auftrag des Gesetzgebers bezüglich der GANZHEITLICHKEIT bei der Betreuung [1] sehr ernst zu nehmen. :."pflege heißt, den Patienten in seiner aktuellen konkreten Situation und Befindlichkeit aufzunehmen, ihn anzunehmen, sich ihm liebevoll zuwenden, ihn umsorgen, sich für ihn einsetzen, ihn gegebenenfalls auf seinem Weg zum Tod zu begleiten. Pflege setzt voraus, dass zwischen Pflegenden und Gepflegten, Beziehungen entstehen, in denen anvertrautes Leiden und Leben gemeinsam getragen werden können. Pflege umfasst daher alle Maßnahmen, die notwendig sind und die dazu beitragen, dass der Patient . würdevoll sterben kann." Welche Maßnahmen zur Anwendung kommen, sollte immer mit dem Schwerkranken, sterbenden Menschen und ggf. mit seinen Angehörigen, Freunden und den professionell Pflegenden abgesprochen werden.